ARKK is having a rough start to 2026. After closing 2025 with a 35.49% return that crushed the S&P 500, Cathie Wood’s ...

CRISPR Therapeutics AG recently reported its fourth-quarter and full-year 2025 results, showing revenue falling to US$0.864 million in Q4 and US$3.51 million for the year, alongside wider net losses ...

CRISPR Therapeutics (NasdaqGM:CRSP) reports material progress in commercializing Casgevy, the first FDA approved gene editing ...

CRISPR Therapeutics’ fourth quarter was relatively disappointing. As a biotech start-up still in its infancy though, these early quarterly numbers don’t mean much. The foreseeable future looks bright ...

CRISPR Therapeutics highlights progress in clinical trials & uptake of Casgevy gene therapy. Pipeline also advancing with promising data.

Vertex Q4 earnings miss estimates, but revenues top forecasts on strong CF sales and momentum from new launches like Alyftrek, Casgevy and Journavx.

Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple ...

Vertex posted revenue and earnings for Q4 and full-year 2025 that hovered around consensus Wall Street estimates, but CRISPR Therapeutics missed expectations.

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. | Vertex expects $500 million in 2026 from new products ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. "As we ...